Skip to content
10-Q

Quarterly Report

Immunoclin Corp

0001517126-14-000229

← back to feed
Filed
Jul 24, 2014 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2014 · Jul 23, 2014 26.48M sh
Capex Q1 2014 · Apr 30, 2014 $4.46K
Operating Cash Flow Q1 2014 · Apr 30, 2014 −$102.58K
Operating Cash Flow Q1 2014 · Apr 30, 2013 −$27.6K
Stockholders Equity Q1 2014 · Apr 30, 2014 $19.06M
Stockholders Equity Q1 2014 · Jan 31, 2014 $19.8M
Stockholders Equity Q1 2014 · Jan 31, 2013 −$310.39K
Current Liabilities Q1 2014 · Apr 30, 2014 $1.15M
Current Liabilities Q1 2014 · Jan 31, 2014 $725.47K
Current Assets Q1 2014 · Apr 30, 2014 $135.44K
Current Assets Q1 2014 · Jan 31, 2014 $74.01K
Total Assets Q1 2014 · Apr 30, 2014 $20.21M
Total Assets Q1 2014 · Jan 31, 2014 $20.53M
Sga Expense Q1 2014 · Apr 30, 2014 $80.54K
Sga Expense Q1 2014 · Apr 30, 2013 $35.88K
Rd Expense Q1 2014 · Apr 30, 2014 $7.96K
Rd Expense Q1 2014 · Apr 30, 2013 $5.1K
Net Income Q1 2014 · Apr 30, 2014 −$793.56K
Net Income Q1 2014 · Jan 31, 2014 −$12.98M
Net Income Q1 2014 · Apr 30, 2013 −$43.88K
Operating Income Q1 2014 · Apr 30, 2014 −$795.87K
Operating Income Q1 2014 · Apr 30, 2013 −$44.55K